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Abstract
Introduction: Stimulation tests form the basis for the diagnostic process in growth hormone deficiency (GHD). One of these tests uses 
the GH releasing hormone (GHRH). This provides the potential to differentiate patients with pituitary dysfunction from patients with 
hypothalamus abnormalities. However, the routine use of the GHRH test is still being debated. The aim of this study was to assess the 
diagnostic usefulness of the GHRH test in the diagnostics of GHD. 
Material and methods: The study group consisted of 20 prepubertal children with GHD. In all the children, one of the performed stimu-
lation tests was the GHRH test. 
Results: The results showed that the mean peak concentration of GH in the GHRH test was 14.7 ± 11.3 ng/mL. In eight children the MRI 
showed pituitary hypoplasia, in one patient pituitary hypoplasia and pituitary stalk agenesis, and in one patient septo-optic dysplasia. 
All patients with pituitary malformations, except for one patient with a hypoplastic pituitary gland, presented GH levels < 10 ng/mL in 
the GHRH test. The sensitivity of the GHRH test in the diagnostics of GHD was 45%. 
Conclusions: The high correlation between the GHRH test and anatomical changes in the pituitary provides this test with a high predic-
tive value. In individual clinical cases, knowledge about the level of damage in the hypothalamic-pituitary area can determine diagnostic 
and therapeutic procedures. (Endokrynol Pol 2015; 66 (2): 137–141)
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Streszczenie 
Wstęp: Testy stymulacyjne są podstawą procesu diagnostycznego niedoboru hormonu wzrostu (GHD). Jednym z takich testów jest test 
z somatoliberyną (GHRH). Umożliwia on odróżnienie pacjentów z zaburzeniami przysadki od pacjentów z zaburzeniami podwzgórza. 
Zasadność stosowania testu z GHRH w rutynowej diagnostyce GHD jest nadal dyskutowana.
Celem pracy była ocena przydatności diagnostycznej testu GHRH w diagnostyce SNP. 
Materiał i metody: Grupę badaną stanowiło 20 dzieci prepubertalnych z GHD. U wszystkich dzieci jednym z przeprowadzonych badań 
był test GHRH. 
Wyniki: Uzyskano następujące wyniki: średnie maksymalne stężenie hormonu w teście GHRH wynosiło 14,7 ng/ml ± 11.3, u 8 dzieci 
stwierdzono hipoplazję przysadki, u 1 pacjenta hipoplazję przysadki i agenezję szypuły przysadki, u 1 — dysplazję przegrodowo-
-wzrokową. U wszystkich pacjentów z nieprawidłowością przysadki, z wyjątkiem jednego pacjenta z hipoplazją przysadki, stężenie GH 
w teście GHRH było < 10 ng/ml. Czułość testu GHRH w diagnostyce GHD wynosiła 45% .
Wnioski: Wysoka korelacja testu GHRH ze zmianami anatomicznymi w przysadce stanowi o wysokiej wartości predykcyjnej testu. 
W indywidualnych przypadkach klinicznych wiedza na temat poziomu uszkodzenia okolicy podwzgórzowo-przysadkowej może określić 
postępowanie diagnostyczne i terapeutyczne. (Endokrynol Pol 2015; 66 (2): 137–141)
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Introduction
The diagnostics of growth hormone secretion is based 
on stimulation tests using pharmacological and physi-
ological provocation, assessing spontaneous GH secre-
tion as 12–24 hours intermittent, or continuous blood 
sampling for GH and determination of the biochemical 
markers of GH action, such as IGF-1 (insulin growth 
factor type 1) and IGFBP-3 (insulin growth factor bind-
ing protein type 3).
None of these tests is a perfect test, a so-called gold 
standard. Each test is associated with the risk of pro-
viding a false result. Therefore, in practice, diagnosis is 
not based on only a single test. The clinical picture and 
auxological data of a child are of great importance in 
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been used for over 30 years are performed to assess the 
pituitary GH reserve. The pharmacological stimulation 
tests use factors that stimulate the secretion of GH by the 
pituitary gland. Most of the stimulating factors that are 
used in these tests act via stimulating the pituitary gland 
by influencing the secretion of hypothalamic neurohor-
mones, such as growth hormone releasing hormone 
(GHRH) and somatotropin release-inhibitory factor 
(SRIF). This mechanism is used in tests with insulin, 
clonidine, arginine, glucagon, and L-dopa [1]. This means 
that in these tests, assessment of GH secretion by the 
pituitary depends on the efficiency of the hypothalamus. 
A defect in the hypothalamus and/or the pituitary gland 
causes an abnormal response to those factors without 
distinguishing the level of damage. From the clinician’s 
viewpoint, wishing to confirm GH deficiency, detecting 
the level of dysfunction is not critical.
The test utilising biosynthetic GHRH makes it pos-
sible to differentiate patients with pituitary dysfunc-
tion from patients with hypothalamus abnormalities. 
In individual cases, establishing the localisation of the 
damage may have an impact on diagnostic and thera-
peutic procedures.
The aim of the study was to assess the diagnostic 
usefulness of the GHRH test in the diagnostics of GHD 
in children.
Material and methods
The study comprised 20 children (12 girls, 8 boys) with 
diagnosed GHD in the Department of Paediatric Endo-
crinology and Rheumatology of Poznan University of 
Medical Sciences. The children were prepubertal, aged 
4–16 years, htSDS was -3.06 ± 0.78, and the BMI of the 
patients compared to age range was normal. 
In all the children, one of the stimulation tests 
performed was the GHRH test. The sleep test (the 
estimation of spontaneous GH secretion during the 
first two hours of sleep, every 30 minutes) and at least 
two different pharmacological tests (with GHRH, 
insulin, clonidine, glucagon) were performed in each 
child. The GHD deficiency observed at peak GH con-
centration was < 10 ng/mL in the sleep test and in the 
two pharmacological tests. A peak GH concentration 
> 10 ng/mL in the GHRH test did not exclude GHD. 
The protocol for the GHRH test was as follows; 
morning, fasting, GHRH (i.v. bolus) 1 mcg/kg. The blood 
samples were taken just before GHRH administration 
and at 15, 30, 45, 60, 90, and 120 minutes after GHRH 
administration. 
The studied patients were not taking any medica-
tions, steroids, or other stimulants that might modify 
the GH secretion. All children admitted to the study 
were clinically and hormonally euthyroid.
Each patient with a diagnosed GH deficiency 
had magnetic resonance imaging (MRI) of the 
head performed. None of the patients presented 
a tumour. The anterior pituitary was considered 
hypoplastic when the height of the pituitary was 
less than two standard deviations compared to 
the normal ranges from Argyropoulou et al. [2]. 
The data obtained was analysed statistically. 
Results 
Mean peak concentration of GH in the GHRH test 
was 14.7 ± 11.3 ng/mL. The highest concentration was 
achieved at 30 minutes and was 11.33 ± 9.5 ng/mL. 
Mean peak concentration of GH in the sleep test 
was 3.8 ± 1.86 ng/mL, in other pharmacological tests 
(no GHRH) — 5.6 ± 2.3 ng/mL. 
In eight children the MRI showed pituitary hypo-
plasia, in one patient it showed pituitary hypoplasia and 
pituitary stalk agenesis, and in one patient septo-optic 
dysplasia. All the patients with pituitary malformation, 
except for the one patient with hypoplastic pituitary, 
showed GH levels < 10 ng/mL in the GHRH test. The 
sensitivity of the GHRH test in diagnosing GHD was 
45%. 
In nine children the GHRH test correlated with 
other stimulation tests. In 11 children with recognised 
GHD following sleep and pharmacological tests, the 
GHRH test showed GH secretion above 10 ng/mL. 
The correlation between peak GH in the GHRH test 
and sleep test in the entire studied group described us-
ing the Pearson correlation coefficient was r = 0.51 and 
was statistically significant (p < 0.05). The correlation 
between peak GH in the GHRH test and other phar-
macological stimulation tests was r = 0.26 and was not 
statistically significant (p = 0.13).
The results are presented in Table I and Figure 1. 
Discussion 
The results confirm the fact that the GHRH test should 
not be used as a basic test in GHD diagnostics in chil-
dren. However, it is useful in organic hypopituitarism 
because there is a high correlation between the GHRH 
test and anatomical changes in the pituitary gland. 
Abnormal synthesis, secretion, and the action of 
GHRH lead to growth hormone deficiency. Both con-
genital and acquired pathologies within the hypothala-
mus may be the cause of GHRH deficiency, followed 
by GH deficiency.
Acquired changes that may cause damage to the hy-
pothalamus are: 1) cranio-cerebral trauma in childhood 
and perinatal trauma associated with hypoxia, forceps, 
and breech birth; 2) intracranial tumours such as cranio-
139












Figure 1. The GH [ng/mL] concentration at different times of blood sampling in GHRH test in the studied group (A). The GH [ng/mL] 
concentration at different times of blood sampling in GHRH test in children with pituitary abnormalities in MRI and in children with 
normal pituitary picture (B)
Rycina 1. Stężenie GH [ng/mL] w różnych oznaczeniach czasowych w teście GHRH w badanej grupie dzieci (A). Stężenie GH [ng/ml] 
w różnych oznaczeniach czasowych w teście GHRH u dzieci z nieprawidłowościami w przysadce w MRI i u dzieci z prawidłowym 
obrazem przysadki (B)
Table I. The characteristics of the studied group, GH concentration in tests performed, and the MRI picture
Tabela I. Charakterystyka badanej grupy, stężenia GH w wykonanych testach stymulacyjnych i obraz MRI




Max GH concentration 
[ng/mL] in GHRH test
Max GH concentration  
[ng/mL] in sleep test
Max GH concentration [ng/mL] in other 
pharmacologic stimulation tests
Pituitary picture  
in MRI
1 14.0 –2.8 9.8 5.5 2.4 (I) HP
2 5.0 –2.0 15.4 3.8 8.3 (C) HP
3 13.0 –2.4 1.9 3.3 2.6 (G) HP
4 5.5 –2.1 5.8 3.4 4.8 (G) HP
5 8.0 –4.1 4.2 1.5 3.0(G) HP + pituitary  
stalk agenesis
6 7.0 –2.8 28.0 3.7 6.7 (G) N
7 6.5 –3.5 29.2 3.1 8.3 (C) N
8 13.5 –3.0 43.3 7.0 5.2 (G) N
9 6.7 –3.1 6.1 1.8 8.8 (G) HP
10 16.0 –4.0 10.3 4.8 3.6 (G) N
11 12.5 –2.7 1.9 2.5 4.2 (C) HP
12 12.0 –3.0 35.3 4.7 5.8 (C) N
13 4.0 –2.5 18.2 7.2 8.9 (G) N
14 12.0 –2.0 6.3 1.6 6.0 (G) SOD
15 4.5 –3.0 17.9 5.0 7.2 (C) N
16 7.5 –2.7 17.7 6.9 4.9 (G) N
17 16.0 –5.0 7.3 1.8 3.5 (I) HP
18 12.0 –3.6 18.0 3.1 3.3 (C) N
19 4.0 –3.0 12.0 1.1 5.3 (G) N
20 6.0 –4.0 8.9 4.2 9.9 HP 
C — clonidine; I — insulin; G — glucagon; HP — hypoplasia of pituitary anterior lobe, SOD — septo-optic dysplasia; N — normal picture
pharyngioma, germinoma, optic glioma, histiocytosis X, 
and the state after operation of a brain tumour; 3) in-
flammation within the cranial cavity (bacterial, viral, 
fungal, parasitic aetiology); 4) cellular infiltration within 
the CNS (sarcoidosis, tuberculosis, haemochromatosis); 
5) cardiopulmonary vascular disorders; and 6) status 
after post-radiotherapy or chemotherapy. 
The type of congenital GHRH deficiency is mainly 
determined by organic lesions. Organic lesions occur 
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such as holoprosencephaly, septo-optic dysplasia, cleft 
lip and palate, abnormal dentition of the upper jaw 
(single central incisor), and herniation of the base of 
the brain. Abnormal development of the midline or-
gans can lead to different types of birth defects within 
the hypothalamus and pituitary glands [3]. Abnormal 
function of the hypothalamus and pituitary may be 
caused by a classic triad of congenital malformations — 
ectopic posterior pituitary lobe, hypoplasia or aplasia 
of anterior pituitary lobe, and pituitary stalk interrup-
tion or agenesis. This is a congenital syndrome that is 
relatively frequently observed in MRIs of the head in 
growth hormone-deficient patients [4]. There are also 
patients described with short stature due to a GHRH-
R defect, e.g. homozygous mutations in the GHRH 
receptor gene [5]. Mutations in the gene encoding the 
GHRH molecule have not yet been detected, which 
may suggest that such defects generate not only GH 
deficiency, but perhaps do not allow proper develop-
ment of the pituitary.
In our examined group, the observed malformations 
of the pituitary were congenital. The most frequent was 
hypoplasia of the pituitary anterior lobe.
One patient had hypoplasia of the anterior lobe, 
associated with agenesis of the pituitary stalk. The next 
patient had a rare syndrome — septo-optic dysplasia. All 
patients with pituitary malformations, except for the one 
with a hypoplastic pituitary gland, presented GH below 
the range in the GHRH test. This shows the high sensitiv-
ity of the GHRH test in detecting pituitary malformations. 
Changes in pituitary shape and size may correlate with 
gland activity, particularly growth hormone secretion. 
There is evidence directly linking pituitary height and 
stature between the age of 8 days and 21 years, and a 
correlation between reduced or absent anterior lobe with 
GH deficiency [2,6]. This study proves that the height of 
the pituitary gland modifies secretion of GH. Patients with 
pituitary hypoplasia and GH secretion close to or above 
10 ng/mL may suggest that the volume of the pituitary 
gland is not the only determinant of pituitary function. 
The accuracy of the MRI examination can also sometimes 
be faulty. Correct interpretation of MRI scans requires an 
understanding of the specific features of the paediatric 
pituitary gland, how it differs from the adult gland and 
changes during development. 
Since there is a biosynthetic analogue of GHRH, 
the neurohormone is used in diagnostics. On the phar-
maceutical market there are now three analogues of 
GHRH: GHRH (1–40), GHRH (1–44), and GHRH (1–29) 
NH2. The last of these is recommended for diagnosis 
and treatment [1].
Studies in healthy children and adults have shown 
that GH concentrations after intravenous bolus injec-
tion of GHRH analogue increases after five minutes 
and reaches maximum concentration between 30 and 
60 minutes [1]. The amounts of GH secreted from the 
pituitary are GHRH dose dependent [7]. The best re-
sponse to GHRH is likely to be reached at a dose of 1 
mcg/kg [8], so this was the dosage used in our group. 
The highest level of GH was observed 30 minutes after 
GHRH administration. 
The studies showed no significant effect of the stage 
of sexual maturation on concentrations of GH in the 
GHRH test [9, 10]. The use of oestrogen priming did not 
change the response of GH after GHRH [11]. This fact 
suggests that sex steroids influence growth hormone 
secretion by modifying the secretion of hypothalamus 
neurohormones. This is a definite advantage of GHRH 
compared to other stimulants used in tests. It has been 
proven that GH peaks after agents acting via the hypo-
thalamus are lower in the prepubertal period compared 
to puberty. It can cause false positive results. We tried 
to choose a very homogenous group, to eliminate 
eventual false results. This is why our study group was 
prepubertal and the BMI was normal, comparing age 
and sex ranges. The prepubertal status of even older 
children was probably caused by delayed bone age and 
low concentration of gonadotropins. 
Side effects during the test are reported very rarely. 
The most common symptoms after administration of 
GHRH are: temporary feeling of warmth, hot flushes, 
a metallic taste in the mouth, slight nausea, vomiting, 
headache, and chest pain. These symptoms are tran-
sient and disappear quickly. Our children did not report 
any adverse events. 
A GH threshold equal to 10 ng/mL, widely used in 
stimulation tests, is also applicable to the GHRH test. 
There are many studies on the optimal cut-off point for 
GH in GHRH test [11]. Ranke estimated GH concentra-
tion after GHRH administration in 86 healthy children. 
The normal range specified in the ± 2 SD for maximum 
GH was from 11.8 to 172.4 ng/mL. Based on these re-
sults, Ranke found a GH threshold equal to 10 ng/mL 
to be the most diagnostically useful [12]. This cutoff 
value was also used in our study in all performed tests. 
Other studies have shown that for a GH cut-off point of 
7–10 ng/mL after GHRH, the specificity of the test is high-
er than 95%, with a sensitivity of 30% [12]. In children 
with growth hormone deficiency caused by organic rea-
sons, GH peaks are lower than in patients with idiopathic 
hypopituitarism [12]. Low GH after stimulation with 
GHRH indicates GHD with high probability, and normal 
GH levels do not exclude GHD. Therefore, this test is 
not often used as a routine diagnostic test. The GHRH 
test is used more for diagnosing the cause of GHD and 
to identify the lesion site (pituitary vs. hypothalamus). 
Due to the fact that GHD in children is largely 
caused by hypothalamic reasons, the GHRH test, ac-
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cording to some authors, has limited usefulness. It was 
found that 76% of children with partial GHD and 39% 
with total GHD identified on the basis of routine tests, in 
the GHRH test presented GH peaks above 10 ng/mL [1]. 
Patients with normal GH secretion in the GHRH 
test but with a low GH in tests such as with clonidine 
or L-dopa are evidence that the background of ab-
normal growth is caused by GHRH deficiency, and 
therefore they should be treated with recombinant GH. 
The presented study confirms that normal GH level 
in GHRH test does not exclude hypopituitarism — 
11 children (55%) out of 20 had GH > 10 ng/mL, all 
with recognised GHD.
The sensitivity of the GHRH test in our group was 
45%. GH levels above 10 ng/mL in the GHRH test did 
not exclude GHD. The test correlated in 9 patients out of 
20 with other tests. Pearson’s r for correlation between 
GHRH test with sleep test was relatively high (r = 0.51) 
and statically significant. It suggests that the physiologi-
cal stimulation test reflects the function of the pituitary 
gland and correlates with pituitary malformations. 
Pearson’s r for correlation between GHRH test with 
other pharmacologic tests was relatively low (r = 0.26, 
p = 0.13). It confirms that the usefulness of GHRH test 
in GHD diagnostics is restricted but has very high pre-
diction level in patients with organic reasons for GHD. 
In patients after radiotherapy there is no correlation 
between the test with GHRH and conventional tests. 
In 80% of patients the GH secretion was higher after 
stimulation with GHRH than after arginine and insulin 
[1]. This shows that radiation damage takes place in the 
first place in the hypothalamic regulatory mechanism. 
With time, after radiation, the response to GHRH 
becomes weaker. This may be due to the damaging ef-
fects of radiation on somatotrophs or the hypofunction 
of these cells because of a chronic lack of stimulation 
by GHRH. In the case of prolonged inactivity of the 
hypothalamus and lack of pituitary gland stimulation, 
the GHRH test can give false positive results. Some 
authors advocate the use of priming with GHRH for 
a week prior to the test with GHRH, if damage to the 
hypothalamus is suspected [13]. 
Conclusions 
Due to its low sensitivity and low correlation with other 
tests, the GHRH test has a low diagnostic usefulness 
in identifying growth hormone deficiency. However, 
due to its very high specificity and small amount of 
side effects, it may be useful as one of the tests applied, 
especially when an organic reason for hypopituitarism 
is suspected. The high correlation between the GHRH 
test and anatomical changes within the pituitary gland 
gives the test a high predictive value. In individual 
clinical cases, knowledge about the site of damage in 
the hypothalamic-pituitary area can determine the 
diagnostic and therapeutic procedures. On the other 
hand it should be emphasised that a normal GH con-
centration in the GHRH test does not exclude pituitary 
insufficiency, due to the frequently occurring hypotha-
lamic aetiology of GH secretion disorders in children.
This work was presented at poster presentation 
during the 20th Symposium of the Polish Society of 
Paediatric Endocrinology (September 2011).
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